Why Deal Accounting Matters

The pharmaceutical industry is well past the time when licensing was seen as merely a supplement to the internal R&D program. Now, it often plays a more important role than the company's internal R&D. As dealmaking becomes a bigger part of the overall pipeline building program, investors will require greater clarity from companies who now can bury external dealmaking costs in one-time write-offs or aggregated clash flow numbers.

by Roger Longman

The industry is now well past the time when licensing was a corporate backstop, seen as a mere supplement to...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Leadership

More from In Vivo